Proposed Placing and Retail Offer

TERMS NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN IN THE SECTION ENTITLED "DEFINITIONS" OF THIS ANNOUNCEMENT.

Gelion plc

("Gelion" or the "Company" or the "Group")

Proposed Placing and Subscription of 10,103,309 New Ordinary Shares

Retail Offer of up to 1,000,000 New Ordinary Shares

Proposed Appointment of Dr Graham Cooley as Non-Executive Director

Gelion (AIM: GELN) the Anglo-Australian battery innovator announces an equity fundraising of approximately £1.5 million (before expenses) by way of the issue of up to 10,103,309 New Ordinary Shares. The proposed Fundraising comprises a Placing of up to 6,539,976 Placing Shares and a Subscription of 3,563,333 Subscription Shares, as detailed below, each at an Issue Price of 15 pence per New Ordinary Share.

The Company is also pleased to announce the proposed appointment of Dr Graham Cooley as a Non-Executive Director. Dr Cooley brings a wealth of relevant experience and knowledge to the Gelion Board through his background in the power, energy storage and hydrogen sectors over more than 35 years. He was previously Business Development Manager at National Power plc, the UK's largest power generator, and CEO of ITM Power plc, the first hydrogen related company quoted on AIM. Graham has been involved in a wide range of corporate transactions and has raised over £600m for UK cleantech SMEs. He has been an active investor in AIM cleantech companies for over a decade and holds a PhD in Materials Physics, an MBA and has several fellowship appointments. Graham is currently a Non-Executive Director of Cadent Gas, Non-Executive Chairman of Light Science Technologies and Non-Executive Director of Cap-XX. Dr Cooley intends to participate in the Fundraising by way of the Placing through the issue of 666,666 Placing Shares at the Issue Price.

The proposed appointment of Dr Cooley to the board of Gelion remains subject to approval from the Company's nominated adviser and completion of the customary due diligence to satisfy itself as to board composition and the suitability of the proposed director for the purpose of the AIM Rules for Nominated Advisers.

A further announcement, including the requisite Schedule 2(g) disclosure required under the AIM Rules for Companies, will be made in due course upon Dr Cooley's appointment to the board of Gelion.

In addition to the Placing and Subscription, the Company intends to provide existing Shareholders who have not taken part in the Placing or Subscription with the opportunity to subscribe for up to 1,000,000 Retail Offer Shares at the Issue Price to raise up to £0.15 million (before fees and expenses) by way of a retail offer to be conducted on the Bookbuild Platform. A separate announcement will be made shortly regarding the Retail Offer and its terms. The Placing and Subscription are not conditional upon the Retail Offer. For the avoidance of doubt, the Retail Offer is not part of the Placing or Subscription.

Highlights of the Fundraising

• Placing and Subscription with new and existing institutional and other investors to raise gross proceeds of approximately £1.5 million.
• Separately, each of the following Directors, namely Steve Mahon, Thomas Maschmeyer, Joycelyn Morton, Michael Davie, John Wood and Amit Gupta have confirmed that they intend to subscribe for, in aggregate, 1,033,330 New Ordinary Shares at the Issue Price following publication of the Company's financial results for the year ended 30 June 2024, expected to be on 27 December 2024.
• The Issue Price represents a discount of approximately 14.3 per cent. to the closing mid-market price of an Ordinary Share of 17.5 pence on 17 December 2024 (being the latest practicable date prior to the release of this Announcement).
• The proposed Retail Offer to raise up to £150,000, via the Bookbuild Platform, for which a separate announcement will be made shortly.
• The net proceeds of the Fundraising will be used to provide additional working capital.
• Admission is expected to take place on or around 24 December 2024.
• Awarding of a grant from the Australian Government in respect of an Advanced Commercial Prototyping Centre ("ACPC") that the Company plans to commission.
• Appointment of Oberon Capital, as its Joint Broker, with immediate effect. Oberon Capital is a trading name of Oberon Investments Limited.

John Wood, CEO of Gelion, commented: "Our team is diligently advancing the commercial readiness of our innovative battery technologies. We are deeply grateful for the continued support of our shareholders and are pleased to welcome new investors joining us in this fundraise. These funds will help us drive forward our goal of integrating Gelion's technologies into global supply chains. A key focus in the short term is securing investment from strategic or corporate partners to establish the ARENA-supported Advanced Cell Prototyping Centre (ACPC). The ACPC will produce prototype cells using our technology, enabling evaluation by end users and supply chain partners.

This marks an important stage in our growth, linking our advanced battery solutions with a global network of partners committed to commercialization. The support of investors and government agencies like ARENA empowers us to deliver on our vision, create value, and solidify Gelion's position in the evolving battery landscape.

I am particularly pleased also that, subject to the completion of customary due diligence, we will be joined by Dr. Graham Cooley in the pursuit of our mission. With his experience and understanding of the process of commercialization of innovation, the interaction of companies with public markets, combined with fundamental understanding of the science behind the products Gelion is developing, Graham will bring very important perspective."

• Graham Cooley, proposed Non-Executive Director of Gelion, commented: 'I am looking forward to joining the Gelion board at the invitation of the Chairman and CEO. I have been closely following the company's progress and am deeply impressed by its Lithium-sulfur battery technology. With world-leading energy density, lower costs, an ethical supply chain, and enhanced safety, Gelion's innovative approach presents a transformative opportunity for the energy storage market. I look forward to contributing to the company's continued growth and success.'

Accelerated Bookbuild

The Placing will be effected by way of an accelerated bookbuild which will be launched immediately following this Announcement, in accordance with the terms and conditions set out in the Appendix to this Announcement, and will be available to new and existing eligible institutional investors.

Cavendish is acting as nominated adviser, joint broker and joint bookrunner in connection with the Placing. Oberon is acting as joint bookrunner in connection with the Placing.

A placing agreement has been entered into today between the Company, Cavendish and Oberon in connection with the Placing. Further details on the Placing, which is subject to the terms and conditions set out in the Appendix to this Announcement, are set out below.

Whilst the Company has already conducted a focused marketing exercise amongst certain Shareholders and other investors, and the Company is pleased with the level of indicative support received to date, there can be no certainty at this time that the Placing will be successful.

The timing for the close of the accelerated bookbuild and allocation of the Placing Shares shall be at the absolute discretion of Cavendish and Oberon, in consultation with the Company. The final number of Placing Shares to be issued pursuant to the Placing will be agreed by Cavendish, Oberon and the Company at the close of the accelerated bookbuild. The result of the Placing will be announced as soon as practicable thereafter. The Placing is not being underwritten.

Corporate Finance Neil McDonald Seamus Fricker Adam Rae ECM/Sales Louise Talbot Graham Hall

Commercialisation milestones and progress

Since the completion of the Company's most recent fundraising in November 2023, the Company has achieved a number of key commercial objectives, each marking a significant step towards Gelion producing a minimum viable product capable of being manufactured at scale and which will be key to securing strategic investment in the future.

The successful integration of the OXLiD business has accelerated the advancement of the Company's proprietary Li-S cell chemistry leading to the prototype fabrication of Gelion "GEN 3" cells. During testing conducted in September 2024, the 12 Ah GEN 3 Li pouch cell delivered an energy density in excess of 400 wh/kg, which is approximately 60% higher than the energy density typically achieved by traditional lithium-ion batteries. GEN 3 also provides a path toward higher safety and extension of cycle life. In achieving this, Gelion's cells can address the potential needs of aerospace and defence manufacturers and could provide a faster route to market for Gelion's technology.

The Company announced joint development agreements with both IONBLOX (November 2023) and Glencore (June 2024) which the Directors believe is a clear signal of the growing interest in Gelion's technology and product development.

In 2024, Gelion has also seen its first commercial order through the Group's Integration Solutions Business. As announced in October this year, Gelion has been selected to supply battery energy storage systems ("BESS") to Group Energy Pty Ltd (part of the larger Borg Group), with the revenue from the circa. £1m contract expected to be recognised in the current financial year. The order marks an important tangible step for Gelion in establishing a new route to market for Gelion's next-generation battery and leverages Gelion's in-house expertise in battery management systems ("BMS") and BESS integration capability, both of which are critical elements in bringing battery technology to commerciality.

Gelion has also devised a proprietary metallurgical recycling process for lithium-ion and lithium sulphur batteries which has the potential to provide an additional opportunity for diversification of revenue streams, simultaneously optimising the cell manufacturing process through the reduction of waste, operating costs and preservation of equipment life. Gelion plans to incubate this technology with the assistance of government grants and is seeking independent investment to allow the team to focus on the core Li-S technology development.

Background to and reasons for the Fundraising

In order to maintain the current trajectory of development, the Board believes that Gelion should scale up its testing and manufacturing capability in order to convert the interest shown by qualified customers in Gelion products. The ability for Gelion to manufacture pouch cells 'in house' is the most cost-efficient route to commercialisation; being significantly less expensive than using external fabricators and the Board views this as key to unlocking strategic investment in the future.

The Company therefore plans to commission an ACPC by Q1 2026 in Sydney, Australia to accelerate this important next step in Gelion's journey with the support of a £2.5 million grant awarded by the Australian Renewable Energy Agency ("ARENA"), an agency of the Australian government (the "Grant"). The Grant will cover 50% of the total cost of the ACPC project which is expected to be £5.0 million including the capital expenditure and the operating expenses of the project, some of which are already in Gelion's cost base (e.g. Li-S employees, Li-S lab etc.). The award of the Grant was subject to detailed due diligence and the finalisation of the definitive funding agreement and underlines the Company's important role in delivering crucial technologies for net zero, by helping to helping to electrify multiple sectors.

The ACPC project has alignment with the objectives of ARENA's Battery Breakthrough Initiative, which was announced by the Australian Government in the 2024-25 Budget to promote the development of battery manufacturing capabilities.

Shareholders should note that the ACPC Grant commencement is subject to Gelion securing appropriate co-funding.

The establishment of the ACPC aligns with Gelion's capital light business model as management believes that the limited investment in the ACPC will potentially lead to licencing and manufacturing partnership opportunities.

Utilisation of ARENA's funding will enable Gelion to accelerate its pathway to scale production and revenue, with the ACPC program targeted to deliver:

• production of c. 2,000 lithium sulfur ("LiS") and silicon sulfur ("SiS") cells per annum for validation with potential commercial offtake partners, toward revenue generation;
• building out key global supply chain partners to underpin commercial scale up;
• third party certification of Gelion sulfur battery safety;
• advanced manufacturing methods to create efficiencies when scaling up production; and
• in-situ-assembly approach to sustainable electrode production giving Gelion a strong advantage in reducing production costs and carbon footprint.

The ACPC project costs include:

• capital expenditure towards equipment enabling the Company to build and test prototype cells at an accelerated pace. Gelion already has circa. 10 qualified customers globally who are ready to test the samples. Gelion will retain complete ownership of any equipment acquired or IP developed whilst being 50% funded by the Grant; and
• operating expenses for the following three years, part of which includes a portion of Gelion's Li-S existing operating costs, which is expected to reduce the Company's operating costs going forwards.

The Company's progress over the last 12 months has led to increased recognition as to the prospectivity of Gelion's solutions and business model across the energy storage industry. This in turn has led to a noticeable strengthening of relationships with customers and supply chain partners across Australia, Asia, Europe, the UK and the US. The Company is encouraged by its ongoing discussions with major industry participants and is seeking to leverage these to secure strategic investment in the medium term. The Board is confident that the net proceeds of the Fundraising will provide sufficient working capital to allow the Company to progress and conclude these negotiations satisfactorily within the next six months. However, there can of course be no certainty that such a transaction will materialise or that it will be offered on terms that are acceptable to the Company.

Acknowledging this risk and the fact that the net proceeds of the Fundraising are not expected to meet the Company's cash requirements for the next 12 months, the Board is taking steps to raise additional funding outside of the Fundraising and proposed strategic investment through equity or debt including seeking independent investment in incubated business units. Alongside this, the Board is prudently considering measures to reduce its cash burn including discontinuing non-core operations, reducing headcount, focusing development activities, and implementing other cost-saving initiatives.

Following the Fundraising, the Board will rigorously review the business to prioritise areas with near- and long-term profitability, positive cash flow, and strategic alignment with Gelion's core strengths to drive commercial progress. If sufficient debt or equity funding cannot be secured during FY25, further cost reductions, scaling back operations, or, in extreme cases, reassessing the Group's viability may be necessary.

Admission and Settlement

Admission of the New Ordinary Shares is expected to occur at 8.00 a.m. on 24 December 2024 (or such later time and/or date as Cavendish, Oberon and the Company may agree, not being later than the Longstop Date), The New Ordinary Shares will, on Admission, rank pari passu in all respects with the Existing Ordinary Shares and will rank in full for all dividends and other distributions declared, made or paid on the New Ordinary Shares after Admission.

The Fundraising consists of the Placing, the Subscription and the Retail Offer and will raise approximately £1.82 million in aggregate (assuming the Retail Offer is taken up in full). The Fundraising is conditional upon the occurrence of Admission. The Placing and Subscription are not conditional upon the Retail Offer. For the avoidance of doubt, the Retail Offer is not part of the Placing or Subscription.

Use of proceeds

The expected application of funds raised in the Fundraising, assuming the Placing, Subscription and Retail Offer are taken up in full, is summarised as follows:

Current trading and prospects

Based on its unaudited management accounts, the Company expects its FY24 results to be:

• Revenue (R&D tax incentives and grant income) for the year ended 30 June 2024 to be c.£2.0 million, in line with market expectations (£2.0 million);
• Adjusted EBITDA loss[1] of approximately £4.8 million, which is £1.1 million lower than FY23 Adjusted EBITDA loss of £5.9 million given tight cost discipline and £0.8 million ahead of market expectations (Adjusted EBITDA loss of £5.6 million); and
• Net cash as at 30 June 2024 of £3.8 million which is c. £1.7 million higher than market expectations.

Throughout FY24, the Company has also had a focus on cost management reducing annualised costs by over £1.0 million by successfully taking steps to limit expenditure where possible.

The current financial year has started strongly, with the Company making good progress across the business to accelerate commercialisation and value realisation, namely:

• In September 2024, Gelion announced the achievement of an important milestone - that its GEN 3 Li-S cell delivered an energy density in excess of 400 wh/kg, which is approximately 60% higher than the energy density typically achieved by 'traditional' lithium-ion batteries. Having achieved this milestone, the Company now is focusing on improving cycle life.
• In September 2024, the Company announced the incorporation of a wholly owned new subsidiary, Battery Minerals Ltd ("Battery Minerals") in the UK, to develop and commercialise the Lithium-ion battery recycling technology acquired from Johnson Matthey in 2023. Battery Minerals has also been awarded a grant of up to £170k by the UK Government's Department of Business and Trade, which will support a more detailed analysis of the technology as well as an increase in the technology readiness level. Gelion believes this may potentially lead to value creation from this non-core IP with limited investment.
• In October 2024, the Company launched the Energy Storage Integration business, with the award of the first commercial order circa. £1 million to supply a BESS to Group Energy Pty Ltd (part of the larger Borg Group). With this order, the Company has accelerated the timetable to commercial revenues of circa. £1 million and positive gross margin to be recognised in this financial year. With limited working capital exposure through good structuring and the use of readily available third-party cells, these projects should enable modest margins but, importantly, margins that are cash flow positive.

Proposed Participation of the Directors

The directors of the Company have confirmed their intention to subscribe for 1,033,336 new Ordinary Shares in aggregate between them (the "Directors' Intended Participation"). As the Company is currently in a close period under MAR until the publication of its full year results for the period ended 30 June 2024 ("Results"), the Directors are not permitted to enter into any arrangement until after publication of the Results (and subject to each not being in possession of any other unpublished price sensitive information at such time). Results are expected to be published on 27 December 2024.

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

2024

All references to time in this announcement are to London time, unless otherwise stated.

FUNDRAISING STATISTICS

• Assumes that all of the Placing Shares and Subscription Shares are issued and that (save for the New Ordinary Shares) no other Ordinary Shares are issued following the date of this announcement prior to Admission.
• Assumes that the Retail Offer is taken up in full
• Assumes transaction costs of approximately £0.24m.

APPENDIX

UK Product Governance Requirements

Solely for the purposes of the product governance requirements Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process which has determined that the Placing Shares are: (i) compatible with an end target market of: (A) retail investors; (B) investors who meet the criteria of professional clients; and (C) eligible counterparties (each as defined in MiFID II (as defined below)); and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "UK Target Market Assessment"). Notwithstanding the UK Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The UK Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the UK Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the UK Target Market Assessment does not constitute an assessment of suitability or appropriateness for the purposes of Chapter 9A or 10A respectively of the FCA Handbook Conduct of Business Sourcebook, or a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

EU Product Governance Requirements

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process which has determined that the Placing Shares are: (i) compatible with an end target market of: (A) retail investors; (B) investors who meet the criteria of professional clients; and (C) eligible counterparties (each as defined in MiFID II); and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "EU Target Market Assessment"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the EU Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the EU Target Market Assessment does not constitute an assessment of suitability or appropriateness for the purposes of MiFID II, or a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

The Terms and Conditions should be read in their entirety.

Introduction

These Terms and Conditions apply to persons making an offer to acquire Placing Shares under the Placing. Each Placee which confirms its agreement to the relevant Joint Bookrunner to subscribe for Placing Shares under the Placing hereby agrees with the relevant Joint Bookrunner and the Company that it will be bound by these Terms and Conditions and will be deemed to have accepted them.

The Company and the Joint Bookrunners may require any Placee to agree to such further terms and/or conditions and/or give such additional warranties and/or representations as they (in their absolute discretion) see fit and/or may require any such Placee to execute a separate placing letter.

By participating in the Placing (such participation to be confirmed in and evidenced by either (i) a recorded telephone conversation or (ii) email correspondence, in either case between representatives of the relevant Joint Bookrunner and the relevant Placee (a "Recorded Commitment")), each Placee will be deemed to have read and understood these Terms and Conditions in their entirety, to be providing the representations, warranties, indemnities, acknowledgements and undertakings contained in these Terms and Conditions, and to be irrevocably offering to participate and acquire Placing Shares on these Terms and Conditions. Such offer shall be deemed to be accepted, and a Placee shall become bound to acquire Placing Shares, when the relevant Joint Bookrunner confirms to such Placee its allocation of Placing Shares. Upon being notified of its allocation of Placing Shares, a Placee shall be contractually committed to acquire the number of Placing Shares allocated to it at the Issue Price.

Each Placee irrevocably represents, warrants, undertakes, agrees and acknowledges (amongst other things) to the Company and the Joint Bookrunners that:

No prospectus

Each Placee, by participating in the Placing, agrees that the content of this Announcement is exclusively the responsibility of the Company and confirms that it has neither received nor relied on any information (other than the Publicly Available Information), representation, warranty or statement made by or on behalf of the Joint Bookrunners or the Company or any other person and neither of the Joint Bookrunners, the Company nor any other person acting on such person's behalf nor any of their respective affiliates has or shall have any liability for any Placee's decision to participate in the Placing based on any other information, representation, warranty or statement. Each Placee acknowledges and agrees that it has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing. No Placee should consider any information in this Announcement or these Terms and Conditions to be legal, tax, business or other advice. Nothing in this paragraph shall exclude the liability of any person for fraudulent misrepresentation.

Details of the Placing Agreement and the Placing Shares

The Joint Bookrunners have entered into the Placing Agreement with the Company pursuant to which, on the terms and subject to the conditions set out in such Placing Agreement, each of the Joint Bookrunners as agent for and on behalf of the Company, have agreed severally, and not jointly or jointly and severally, to use their reasonable endeavours to procure Placees for the Placing Shares at the Issue Price. The Placing is not being underwritten by either of the Joint Bookrunners

Application for admission to trading

It is expected that Admission will take place on the Admission Date and that dealings in the Placing Shares on AIM will commence at the same time.

Principal terms of the Placing

• Cavendish is acting as nominated adviser, joint broker and joint bookrunner to the Placing, as agent for and on behalf of the Company.
• Oberon is acting as joint broker and joint bookrunner to the Placing, as agent for and on behalf of the Company.
• Participation in the Placing is by invitation only and will only be available to persons who may lawfully be, and are, invited by the Joint Bookrunners to participate. The Joint Bookrunners and any of their affiliates are entitled to participate in the Placing as principal.
• Each Placee's allocation will be confirmed to Placees orally, or in writing (which can include email), by the relevant Joint Bookrunner and a trade confirmation or contract note will be dispatched as soon as possible thereafter. The relevant Joint Bookrunner's oral or written confirmation will give rise to an irrevocable, legally binding commitment by that Placee, in favour of the relevant Joint Bookrunner and the Company, under which it agrees to acquire by subscription the number of Placing Shares allocated to it at the Issue Price and otherwise on these Terms and Conditions. Except with the consent of the relevant Joint Bookrunner, such commitment will not be capable of variation or revocation.
• The Issue Price is payable to the relevant Joint Bookrunner (as agent for the Company) by all Placees.
• Each Placee's allocation and whether such Placee participates in the Placing will be determined by the relevant Joint Bookrunner in its reasonable discretion following consultation with the Company and will be confirmed by the relevant Joint Bookrunner.
• Each Placee's commitment will be confirmed in and evidenced by a Recorded Commitment. These Terms and Conditions will be deemed incorporated into the contract which is entered into by way of a Recorded Commitment and will be legally binding on the relevant Placee(s) on behalf of whom the commitment is made with effect from the end of the Recorded Commitment and, except with the relevant Joint Bookrunner's prior written consent, will not be capable of variation or revocation after such time. Without prejudice to the foregoing, a contract note recording each Placee's commitment will be sent to them following the Recorded Commitment. These Terms and Conditions shall be deemed incorporated into any such contract note.
• Each Placee will confirm the maximum number of Placing Shares it is willing to acquire in a Recorded Commitment. Once they have made a Recorded Commitment, each Placee will have an immediate, separate, irrevocable and binding obligation, owed to the relevant Joint Bookrunner (as agent for the Company), to pay to it (or as it may direct) in cleared funds an amount equal to the product of the Issue Price and the number of Placing Shares such Placee has agreed to acquire.
• The Joint Bookrunners reserve the right to scale back the number of Placing Shares to be subscribed by any Placee in the event that the Placing is oversubscribed. The Joint Bookrunners also reserve the right not to accept offers to subscribe for Placing Shares or to accept such offers in part rather than in whole. The acceptance and, if applicable, scaling back of offers shall be at the absolute discretion of the Joint Bookrunners.
• To the fullest extent permissible by law and applicable FCA rules, neither:
• either of the Joint Bookrunners;
• either of the Joint Bookrunner's affiliates, agents, advisers, directors, officers, consultants or employees; nor
• to the extent not contained within (a) or (b), any person connected with either of the Joint Bookrunners as defined in the FSMA ((b) and (c) being together "affiliates" and individually an "affiliate" of each of the Joint Bookrunners),

shall have any liability (including to the extent permissible by law, any fiduciary duties) to Placees or to any other person whether acting on behalf of a Placee or otherwise. In particular, neither of the Joint Bookrunners nor any of their respective affiliates shall have any liability (including, to the extent permissible by law, any fiduciary duties) in respect of their conduct of the Placing or of such alternative method of effecting the Placing as the Joint Bookrunners and the Company may agree.

Registration and settlement

Settlement of transactions in the Placing Shares following Admission will take place within the CREST system, subject to certain exceptions. Settlement through CREST will be on a delivery versus payment basis ("DVP") unless otherwise notified by the Joint Bookrunners and is expected to occur on the Admission Settlement Date.

However, in the event of any difficulties or delays in the admission of the Placing Shares to CREST or the use of CREST in relation to the Placing, the Company and each of the Joint Bookrunners may agree that the Placing Shares (or any of them) should be issued in certificated form. Each of the Joint Bookrunners reserves the right to require settlement for any of the Placing Shares, and to deliver any of the Placing Shares to any Placees, by such other means as they deem necessary if delivery or settlement to any Placee is not practicable within the CREST system or would not be consistent with regulatory requirements in the jurisdiction in which a Placee is located.

Interest is chargeable daily on payments not received from Placees on or before the due date in accordance with the arrangements set out above, in respect of either CREST or certificated deliveries, at the rate of 3 percentage points above prevailing base rate of Barclays Bank plc as determined by the Joint Bookrunners.

Each Placee is deemed to agree that if it does not comply with these obligations, the Joint Bookrunners may sell any or all of their Placing Shares on their behalf and retain from the proceeds, for the Company's own account and benefit, an amount equal to the aggregate amount owed by the Placee plus any interest due. The relevant Placee will, however, remain liable for any shortfall below the Issue Price and for any stamp duty or stamp duty reserve tax (together with any interest or penalties) which may arise upon the sale of its Placing Shares on its behalf.

Conditions of the Placing

The obligations of the Joint Bookrunners under the Placing Agreement are, and the Placing of the Placing Shares is, conditional upon, inter alia:

• the warranties and undertakings contained in the Placing Agreement ("Warranties") being, in all material respects, true, accurate and not misleading when made on the date of the Placing Agreement and at Admission by reference to the facts and circumstances subsisting at that time;
• the Joint Bookrunners not having exercised their rights to terminate the Placing Agreement; and
• Admission having occurred on or before 8.00 am on the Admission Date.

All conditions to the obligations of the Joint Bookrunners included in the Placing Agreement are together referred to in these Terms and Conditions as the "conditions".

If any of the conditions is not fulfilled or, where permitted, waived in accordance with the Placing Agreement within the stated time periods (or such later time and/or date as the Company and the Joint Bookrunners may agree), or the Placing Agreement is terminated in accordance with its terms, the Placing (or such part of it as may then remain to be completed) will lapse and the Placee's rights and obligations shall cease and terminate at such time and each Placee agrees that no claim can be made by or on behalf of the Placee (or any person on whose behalf the Placee is acting) in respect thereof.

The Joint Bookrunners may, in their absolute discretion and upon such terms as it thinks fit, waive fulfilment of all or any of the conditions in the Placing Agreement which are capable of waiver, in whole or in part, or extend the time provided for fulfilment of one or more conditions, save that certain conditions (including the condition relating to Admission referred to in paragraph (c) above) may not be waived. Any such extension or waiver will not affect Placees' commitments as set out in these Terms and Conditions.

Neither of the Joint Bookrunners nor any of their affiliates, agents, advisers, directors, officers or employees nor the Company shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision any of them may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition to the Placing (or any part thereof) nor for any decision any of them may make as to the satisfaction of any condition or in respect of the Placing generally (or any part thereof) and by participating in the Placing each Placee agrees that any such decision is within the absolute discretion of the Joint Bookrunners.

Termination of the Placing

Either of the Joint Bookrunners may, in their absolute discretion, by notice to the Company, terminate the Placing Agreement at any time up to Admission if, inter alia:

• any statement contained in the Announcement, the investor presentation relating to the Fundraising or the Circular (the "Placing Documents") has become or been discovered to be untrue, incorrect or misleading in any material respect, or there is a material mistake or inaccuracy in the Placing Documents, or any matter has arisen which would, if the Placing Documents were issued at that time, constitute a material omission from the Placing Documents or any of them or there arises any material new factor, mistake or inaccuracy relating to the information in the Placing Documents;
• any of the Warranties was untrue, inaccurate or misleading in any material respect when made and/or that any of the Warranties has ceased to be true or accurate or has become misleading in any material respect at any time prior to Admission, in each case by reference to the facts and circumstances subsisting at that time;
• any matter has arisen giving an entitlement on the part of any indemnified person to make a claim under the indemnity contained in the Placing Agreement in any material respect;
• the Company has not complied or cannot comply with any of its obligations under the Placing Agreement or otherwise relating to the Placing (to the extent that such obligations falls due to be undertaken prior to Admission) and which is material in the context of the Company, the Placing Agreement or the Fundraising; or
• there has been a force majeure event which in the opinion of the relevant Joint Bookrunner, is, will or may be materially prejudicial to the Company or to the successful outcome of the Placing.

By participating in the Placing, each Placee agrees with the Company and the Joint Bookrunners that the exercise by the Company or either of the Joint Bookrunners of any right of termination or any other right or other discretion under the Placing Agreement shall be within the absolute discretion of the Company or the Joint Bookrunners or for agreement between the Company and the Joint Bookrunners (as the case may be) and that neither the Company nor either of the Joint Bookrunners need make any reference to such Placee and that neither of the Company, the Joint Bookrunners nor any of their respective affiliates, agents, advisers, directors, officers or employees shall have any liability to such Placee (or to any other person whether acting on behalf of a Placee or otherwise) whatsoever in connection with any such exercise.

By agreeing with the relevant Joint Bookrunner as agent of the Company to subscribe for Placing Shares under the Placing, a Placee (and any person acting on a Placee's behalf) will irrevocably acknowledge and confirm and warrant and undertake to, and agree with, each of the Company and the relevant Joint Bookrunner, in each case as a fundamental term of such Placee's application for Placing Shares and of the Company's obligation to allot and/or issue any Placing Shares to it or at its direction, that its rights and obligations in respect of the Placing (or any part of it) will terminate only in the circumstances described above and under the "Conditions of the Placing" section above and will not be capable of rescission or termination by it in any other circumstances.

Representations, warranties and further terms

By participating in the Placing, each Placee (and any person acting on such Placee's behalf) represents, warrants, acknowledges, undertakes, confirms and agrees with each of the Joint Bookrunners (for itself and for any such prospective Placee) that (save where the Joint Bookrunners expressly agree in writing to the contrary):

• is required under any applicable law; and
• has been or will be prepared in connection with the Placing,
• it has made its own assessment of the Placing Shares and the terms of the Placing and has relied on its own investigation of the business, financial position and other aspects of the Company in accepting a participation in the Placing and neither of the Joint Bookrunners nor the Company nor any of their respective affiliates, agents, advisers, directors, officers or employees nor any person acting on behalf of any of them has provided, and will not provide, it with any material regarding the Placing Shares or the Company or any other person other than the information in the Announcement and these Terms and Conditions or the Publicly Available Information; nor has it requested from the Joint Bookrunners, the Company, any of their respective affiliates, agents, advisers, directors, employees or officers or any person acting on behalf of any of them to provide it with any such information;
• neither of the Joint Bookrunners nor any person acting on behalf of them nor any of their respective affiliates, agents, directors, officers or employees has or shall have any liability for any Publicly Available Information, or any representation relating to the Company, provided that nothing in the Terms and Conditions excludes the liability of any person for any fraudulent misrepresentation made by that person;

6.

• neither of the Joint Bookrunner's nor any of their affiliates, agents, directors, officers or employees have made any representation or warranty to it, express or implied, with respect to the Company, the Placing or the Placing Shares or the accuracy, completeness or adequacy of the Placing Documents or the Publicly Available Information;
• the content of the Announcement and the other Publicly Available Information as well as any information made available (in written or oral form) in presentations or as part of roadshow discussions with investors relating to the Company (the "Information") has been prepared by and is exclusively the responsibility of the Company and that neither the Joint Bookrunners nor any persons acting on their behalf are responsible for or has or shall have any liability for any such Information, representation, warranty or statement relating to the Company contained therein nor will they be liable for any Placee's decision to participate in the Placing based on any Information or any representation, warranty or statement contained therein or otherwise. Nothing in these Terms and Conditions shall exclude any liability of any person for fraudulent misrepresentation;
• it has the funds available to pay for the Placing Shares which it has agreed to acquire and acknowledges and agrees that it will pay the total subscription amount in accordance with these Terms and Conditions by the due time and date set out herein, failing which the relevant Placing Shares may be placed with other Placees or sold at such price as the Joint Bookrunners determine;
• it and/or each person on whose behalf it is participating:
• has fully observed such laws and regulations;
• it will not offer, sell, transfer, pledge or otherwise dispose of any Placing Shares except:
• pursuant to another exemption from registration under the Securities Act, if available,
• it understands that the Placing Shares are expected to be issued to it through CREST but may be issued to it in certificated, definitive form and acknowledges and agrees that the Placing Shares will, to the extent they are delivered in certificated form, bear a legend to the following effect unless agreed otherwise with the Company and the Joint Bookrunners:
• neither the Joint Bookrunners, nor their affiliates or any person acting on behalf of any of them is making any recommendations to it or advising it regarding the suitability of any transactions it may enter into in connection with the Placing and that participation in the Placing is on the basis that it is not and will not be a client of either of the Joint Bookrunners and that no Joint Bookrunner has any duties or responsibilities to it for providing the protections afforded to its clients or for providing advice in relation to the Placing nor in respect of any representations, warranties, undertakings or indemnities contained in the Placing Agreement nor for the exercise or performance of any of its rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right;
• it will make payment to the relevant Joint Bookrunner for the Placing Shares allocated to it in accordance with these Terms and Conditions on or by the specified time (being the Admission Settlement Date in respect of any Placing Shares), failing which the relevant Placing Shares may be placed with others on such terms as the Joint Bookrunners determine in their absolute discretion without liability to the Placee and it will remain liable for any shortfall below the net proceeds of such sale and the placing proceeds of such Placing Shares and may be required to bear any stamp duty or stamp duty reserve tax (together with any interest or penalties due pursuant to the terms set out or referred to in these Terms and Conditions) which may arise upon the sale of such Placee's Placing Shares on its behalf;
• its allocation (if any) of Placing Shares will represent a maximum number of Placing Shares which it will be entitled, and required, to subscribe for, and that the relevant Joint Bookrunner may call upon it to subscribe for a lower number of Placing Shares (if any), but in no event in aggregate more than the aforementioned maximum;
• the person who it specifies for registration as holder of the Placing Shares will be:
• the Placee; or
• a nominee of the Placee, as the case may be;
• neither of the Joint Bookrunners or the Company will be responsible for any liability to stamp duty or stamp duty reserve tax payable on the acquisition of the Placing Shares. Each Placee and any person acting on behalf of such Placee agrees to acquire Placing Shares pursuant to the Placing and agrees to indemnify the Company and each of the Joint Bookrunners in respect of the same on the basis that the Placing Shares will be allotted to a CREST stock account of either of the Joint Bookrunners or transferred to a CREST stock account of either of the Joint Bookrunners who will hold them as nominee on behalf of the Placee until settlement in accordance with its standing settlement instructions with it;
• as far as it is aware it is not acting in concert (within the meaning given in The City Code on Takeovers and Mergers) with any other person in relation to the Company, save as previously disclosed to the Joint Bookrunners;
• it has only communicated or caused to be communicated and it will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) relating to Placing Shares in circumstances in which section 21(1) of the FSMA does not require approval of the communication by an authorised person and it acknowledges and agrees that neither these Terms and Conditions nor the Announcement has not been approved by either of the Joint Bookrunners in their capacity as an authorised person under section 21 of the FSMA and it may not therefore be subject to the controls which would apply if it was made or approved as financial promotion by an authorised person;
• the Placing Shares acquired by it in the Placing will not be acquired on a non-discretionary basis on behalf of, nor will they be acquired with a view to their offer or resale to, any person save in circumstances in which the express prior written consent of the Joint Bookrunners has been given to the offer or resale;
• dealt (or attempted to deal) in the securities of the Company;
• encouraged, recommended or induced another person to deal in the securities of the Company; or
• neither of the Joint Bookrunners, the Company nor any of their respective affiliates, agents, advisers, directors, officers or employees nor any person acting on behalf of the Joint Bookrunners or their affiliates, agents, advisers, directors, officers or employees nor any person acting on behalf of any of them is making any recommendations to it, advising it regarding the suitability of any transactions it may enter into in connection with the Placing nor providing advice in relation to the Placing nor in respect of any representations, warranties, acknowledgements, agreements, undertakings, or indemnities contained in the Placing Agreement nor the exercise or performance of any of the Joint Bookrunner's rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right;
• the Joint Bookrunners and their affiliates, acting as an investor for its or their own account(s), may bid or subscribe for and/or purchase Placing Shares and, in that capacity, may retain, purchase, offer to sell or otherwise deal for its or their own account(s) in the Placing Shares, any other securities of the Company or other related investments in connection with the Placing or otherwise. Accordingly, references in the Announcement and/or these Terms and Conditions to the Placing Shares being offered, subscribed, acquired or otherwise dealt with should be read as including any offer to, or subscription, acquisition or dealing by, the Joint Bookrunners and/or any of their affiliates acting as an investor for its or their own account(s). Neither of the Joint Bookrunners nor the Company intend to disclose the extent of any such investment or transaction otherwise than in accordance with any legal or regulatory obligation to do so;
• it:
• is not a person:

(all such statutes, rules and regulations referred to in this paragraph 37 together, the "Regulations") and if making payment on behalf of a third party, satisfactory evidence has been obtained and recorded by it to verify the identity of the third party as required by the Regulations and it has obtained all governmental and other consents (if any) which may be required for the purpose of, or as a consequence of, such purchase, and it will provide promptly to the Joint Bookrunners such evidence, if any, as to the identity or location or legal status of any person which they may request from it in connection with the Placing (for the purpose of complying with the Regulations or ascertaining the nationality of any person or the jurisdiction(s) to which any person is subject or otherwise) in the form and manner requested by the Joint Bookrunners on the basis that any failure by it to do so may result in the number of Placing Shares that are to be acquired by it or at its direction pursuant to the Placing being reduced to such number, or to nil, as the Joint Bookrunners may decide in their discretion;

38. in order to ensure compliance with the Regulations, the Joint Bookrunners (each for themselves and as agent on behalf of the Company) or the Company's registrars may, in their absolute discretion, require verification of its identity. Pending the provision to the Joint Bookrunners or the Company's registrars, as applicable, of evidence of identity, definitive certificates in respect of the Placing Shares may be retained at the Joint Bookrunners' absolute discretion or, where appropriate, delivery of the Placing Shares to it in uncertificated form may be delayed at the Joint Bookrunners' or the Company's registrars', as the case may be, in their absolute discretion. If within a reasonable time after a request for verification of identity the Joint Bookrunners (each for themselves and as agent on behalf of the Company) or the Company's registrars have not received evidence satisfactory to them, either the Joint Bookrunners and/or the Company may, at their absolute discretion, terminate their commitment in respect of the Placing, in which event the monies payable on acceptance of allotment will, if already paid, be returned without interest to the account of the drawee's bank from which they were originally debited;

• its commitment to acquire Placing Shares on the Terms and Conditions will continue notwithstanding any amendment that may in future be made to the terms and conditions of the Placing and that Placees will have no right to be consulted or require that their consent be obtained with respect to the Company's or the Joint Bookrunners' conduct of the Placing;
• it irrevocably appoints any duly authorised officer of any of the Joint Bookrunners as its agent for the purpose of executing and delivering to the Company and/or its registrars any documents on its behalf necessary to enable it to be registered as the holder of any of the Placing Shares which it agrees to acquire upon the these Terms and Conditions;
• the Company, the Joint Bookrunners and others (including each of their respective affiliates, agents, advisers, directors, officers and employees) will rely upon the truth and accuracy of the foregoing representations, warranties, acknowledgements and agreements, which are given to the Joint Bookrunners, each on their own behalf and on behalf of the Company and are irrevocable;
• time is of the essence as regards its obligations under these Terms and Conditions;
• the Placing Shares will be issued subject to these Terms and Conditions; and
• these Terms and Conditions and all documents into which these Terms and Conditions are incorporated by reference or of which they otherwise validly form a part and/or any agreements entered into pursuant to these Terms and Conditions and all agreements to acquire Placing Shares pursuant to the Placing will be governed by and construed in accordance with English law and it submits to the exclusive jurisdiction of the English courts in relation to any claim, dispute (contractual or otherwise) or matter arising out of or in connection with such contract except that enforcement proceedings in respect of the obligation to make payment for the Placing Shares (together with interest chargeable thereon) may be taken by the Company or the Joint Bookrunners in any jurisdiction in which the relevant Placee is incorporated or in which any of its securities have a quotation on a recognised stock exchange.

By participating in the Placing, each Placee (and any person acting on such Placee's behalf) agrees to indemnify and hold the Company, the Joint Bookrunners and each of their respective affiliates, agents, directors, officers and employees harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the representations, warranties, acknowledgements, agreements and undertakings given by the Placee (and any person acting on such Placee's behalf) in these Terms and Conditions or incurred by the Joint Bookrunners, the Company or any of their respective affiliates, agents, directors, officers or employees arising from the performance of the Placee's obligations as set out in these Terms and Conditions, and further agrees that the provisions of these Terms and Conditions shall survive after the completion of the Placing.

The agreement to allot and issue Placing Shares to Placees (or the persons for whom Placees are contracting as agent) free of stamp duty and stamp duty reserve tax in the United Kingdom relates only to their allotment and issue to Placees, or such persons as they nominate as their agents, directly by the Company. Such agreement assumes that the Placing Shares are not being acquired in connection with arrangements to issue depositary receipts or to transfer the Placing Shares into a clearance service. If there are any such arrangements, or the settlement related to any other dealings in the Placing Shares, stamp duty or stamp duty reserve tax may be payable. In that event, the Placee agrees that it shall be responsible for such stamp duty or stamp duty reserve tax and neither the Company nor the Joint Bookrunners shall be responsible for such stamp duty or stamp duty reserve tax. If this is the case, each Placee should seek its own advice and they should notify the Joint Bookrunners accordingly. In addition, Placees should note that they will be liable for any capital duty, stamp duty and all other stamp, issue, securities, transfer, registration, documentary or other duties or taxes (including any interest, fines or penalties relating thereto) payable outside the United Kingdom by them or any other person on the acquisition by them of any Placing Shares or the agreement by them to acquire any Placing Shares and each Placee, or the Placee's nominee, in respect of whom (or in respect of the person for whom it is participating in the Placing as an agent or nominee) the allocation, allotment, issue or delivery of Placing Shares has given rise to such non-United Kingdom stamp, registration, documentary, transfer or similar taxes or duties undertakes to pay such taxes and duties, including any interest and penalties (if applicable), forthwith and to indemnify on an after-tax basis and to hold harmless the Company and the Joint Bookrunners in the event that either of the Company and/or the Joint Bookrunners have incurred any such liability to such taxes or duties.

The representations, warranties, acknowledgements and undertakings contained in these Terms and Conditions are given to each Joint Bookrunner for itself and on behalf of the Company and are irrevocable.

The provisions of these Terms and Conditions may be varied, waived or modified as regards specific Placees or on a general basis by the Joint Bookrunners provided always that such variation, waiver or modification is not materially prejudicial to the interests of the Company.

Each Placee and any person acting on behalf of the Placee acknowledges and agrees that the Joint Bookrunners may (at their absolute discretion) satisfy their obligations to procure Placees by themselves agreeing to become a Placee in respect of some or all of the Placing Shares or by nominating any connected or associated person to do so.

When a Placee or any person acting on behalf of the Placee is dealing with a Joint Bookrunner, any money held in an account with the relevant Joint Bookrunner on behalf of the Placee and/or any person acting on behalf of the Placee will not be treated as client money within the meaning of the relevant rules and regulations of the FCA made under the FSMA. Each Placee acknowledges that the money will not be subject to the protections conferred by the client money rules: as a consequence this money will not be segregated from the relevant Joint Bookrunner 's money in accordance with the client money rules and will be held by it under a banking relationship and not as trustee.

References to time in the Terms and Conditions are to London time, unless otherwise stated.

DEFINITIONS

The following definitions apply to these Terms and Conditions:

[1] Excludes non-recurring expenses such as net loss on sales of fixed assets, IP write off, transaction costs, and other associated costs and share based payments.